- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06836232
En open-label pilotundersøgelse af VTX2735 i tilbagevendende pericarditis
En fase 2A, open-label-pilotundersøgelse for at evaluere sikkerheden/tolerabiliteten, effektiviteten, farmakokinetikken og farmakodynamikken af VTX2735 hos deltagere med tilbagevendende pericarditis
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).
Cohort A will include approximately 10 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A
- A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A
- An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Cohort B will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C
- A 14-day Follow-Up Period
Cohort C will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Ventyx Clinical Trial Contact
- Telefonnummer: ext 108 888-411-5176
- E-mail: ClinicalTrials@ventyxbio.com
Studiesteder
-
-
-
Ghent, Belgien, 9000
- Rekruttering
- Local Site #056001
-
Leuven, Belgien, 3000
- Rekruttering
- Local Site #056002
-
-
-
-
-
Montreal, Canada, H4A 3J1
- Ikke rekrutterer endnu
- Local Site #840102
-
Ottawa, Canada, K1Y 4S7
- Rekruttering
- Local Site #840101
-
-
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Site Location #840023
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- Local Site #840014
-
-
Florida
-
Saint Augustine, Florida, Forenede Stater, 32086
- Rekruttering
- Local Site #840016
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Local Site #840008
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Local Site #840010
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905-0002
- Rekruttering
- Local Site #840005
-
Ledende efterforsker:
- Sushil Luis
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Local Site #840020
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Local Site #840017
-
-
Texas
-
Houston, Texas, Forenede Stater, 77034
- Rekruttering
- Local Site #840001
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Local Site #840019
-
Ledende efterforsker:
- Maan Malahfji
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Rekruttering
- Local Site #840013
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05401
- Rekruttering
- Local Site #840022
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Local Site #840004
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Local Site #840018
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Local Site #840021
-
-
-
-
-
Athens, Grækenland, 11527
- Ikke rekrutterer endnu
- Local Site #300001
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants are male or female ≥ 18 years up to ≤ 75 years of age.
- Capable of giving signed informed consent and able to comply with the protocol
- Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
- Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
- CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
- Pericarditis pain score ≥ 4 based on the 11-point NRS.
- Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)
Exclusion Criteria:
- Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
- History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
- Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Kohorte A
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Kohort B -behandlingsgruppe B1
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Kohort B -behandlingsgruppe B2
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Cohort C Treatment Group C1
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Cohort C Treatment Group C2
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of VTX2735
Tidsramme: Day 1 of treatment period through study completion, up to 26 weeks
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation |
Day 1 of treatment period through study completion, up to 26 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of VTX2735 on pericardial pain
Tidsramme: Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in Numeric Pain Rating Scale (NRS) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
|
Effect of VTX2735 on inflammation
Tidsramme: Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in High-Sensitivity C-Reactive Protein (hs-CRP) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 27930
- VTX2735-202 (Anden identifikator: Ventyx Biosciences, Inc.)
- J7W-MC-ELCA (Anden identifikator: Eli Lilly and Company)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .